Deals

French public sector investment bank Bpifrance's influence over the future strategy of Opella extends to its one seat on the company's board, but not past that, Sanofi confirms as it reports Q3 results.

Bayer hopes Impli's implantable hormone biosensor will reveal self-care opportunities in the areas of stress, sleep, weight management, cardiovascular health, women’s health, or bone health.

After coming under fire from French politicians and workers unions over its proposal to sell a majority stake in its consumer health business to US private-equity firm CD&R, Sanofi has invited the French state in on the deal and made a number of binding commitments to jobs and investment.

Control of Sanofi Consumer Healthcare – recently rebranded as Opella – may soon pass to US private-equity firm CD&R but the French firm looks set to retain a substantial stake in a business which has some big Rx-to-OTC switches in the pipeline.

A leading provider of over-the-counter health and wellbeing products in the DACH region will be created through the merger of Merz Lifecare and Windstar Medical.

Perelel acquiring Loom online platform providing reproductive health, sexual wellness and parenting education. First direct-to-consumer product for Curive Healthcare’s Plum brand formulated for vaginal area dryness.

Joint venture business which markets Haleon's OTC drug brands in China will soon be 88% owned by the UK-based firm.

Orifarm has announced details of a strategic investment from Carlyle Global Credit, which the Danish firm says will “strengthen Orifarm’s ongoing expansion, both organic and inorganic.”

“We're significantly investing more in reaching more consumers, but we're doing it in a very different way,” says CGO Charmaine England. Brands may be “iconic,” but on their own they’re not driving sales growth, says CEO Thibaut Mongon.

Haleon CEO Brian McNamara and Bayer Consumer Health president Julio Triana independently tell the Barclays Consumer Conference that their respective firms are unlikely to secure any transformational mergers or acquisitions in the medium term. Both companies are prioritizing bolt-on acquisitions for the next few years.

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Haleon will launch Futura Medical's FDA-approved OTC medical device for erectile dysfunction in the US before the end of the year. Already available to pre-order online on Amazon, Eroxon represents the firm's first move into the sexual health category. 

An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.

Clue Plus members will have access to 50% off a Headspace subscription for tailored guidance, support and validation to help manage cycle-related stress and improve overall well-being.

Germany's Stada Arzneimittel has secured the rights to market the FITO self-care medical device in the Gulf Cooperation Council region, North Africa, the Middle East and selected Asian Countries, and the Nizoral antifungal cream in Vietnam, the Philippines and Thailand. Stada’s half-year results show that the company’s emerging markets strategy is delivering results, with  MENA and APAC contributing to the growth recorded by the Consumer Healthcare division.

Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.

Unilever hopes to double the value of its product innovations this year, ultimately targeting as many as 12 innovations, each costing more than €100m, beginning in 2025, CEO Hein Schumacher says during 25 July earnings presentation.

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Cooper Consumer Health has closed its acquisition of Viatris' OTC business as it commits to divesting the rights to infant laxative medicine Bebegel and earwax removal product Otowaxol in certain markets.

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.